Physician-Guided Deprescribing · Clinical Guide
Controlled-Substance Deprescribing: A Structured, Individualized Clinical Approach
Questions about dose reduction involving benzodiazepines, sedative-hypnotics, and certain related medications may raise important clinical considerations. Treatment planning involves individualized assessment of dosage, duration of exposure, prior taper attempts, withdrawal sensitivity, and overall stability.
Care is provided personally by Christian S. Monsalve, M.D., a board-certified psychiatrist specializing in precision medication tapering and psychiatric deprescribing — available only in jurisdictions where the physician is appropriately licensed.
What is controlled-substance deprescribing?
Controlled-substance deprescribing is the structured, physician-guided reduction of medications such as benzodiazepines and sedative-hypnotics when continued use no longer aligns with clinical benefit. It is individualized rather than protocol-driven — dose reduction is not appropriate in every case.
Why prior failed tapers matter
Some individuals seek consultation after prior taper attempts have been poorly tolerated, incomplete, or clinically destabilizing. A prior failed taper often means the prior method was too fast, too rigid, or insufficiently individualized — it should change the next plan rather than disqualify the patient from trying again.
Before the First Reduction
Clinical Evaluation Before Deprescribing
Before any reduction is initiated, the clinical context must be carefully evaluated — current dosage, frequency and pattern of use, duration of exposure, prior taper attempts, and the presence of inter-dose withdrawal symptoms.
01
Medication and current dosage
The specific medication, current dose, and dosing frequency.
02
Duration of use
How long the medication has been taken, and in what pattern.
03
Prior taper attempts and withdrawal history
Previous attempts at dose reduction and the presence of withdrawal symptoms.
04
Co-occurring conditions
Co-occurring psychiatric or medical conditions, and other medications or sedating substances.
05
Sleep and substance use history
Sleep disturbance and substance use history relevant to withdrawal risk.
06
Functional stability and goals
Overall functional stability, available support, and the patient’s own goals for treatment.
Individualized by Design
Factors That Shape a Tapering Plan
Tapering schedules are not fixed. They are adjusted over time based on symptom response, tolerability, and overall clinical stability.
Pharmacology of the medication
Withdrawal sensitivity, prior unsuccessful reductions, and dose–occupancy relationships all shape whether reductions proceed directly or require alternative pacing, precision, or formulation strategies.
Physiologic response to change
Individual response to each reduction guides the size and timing of the next step.
Symptoms between doses
Inter-dose symptoms and prior difficulty reducing medication inform pacing and formulation choices.
Life context and stability
Functional demands, support, and the patient’s tolerance for change shape a sustainable pace.
Safety Through Patience
Why Gradual Reduction Matters
In some circumstances, progressively paced dose reductions may warrant consideration, particularly where withdrawal sensitivity or prior unsuccessful reductions have occurred. Careful clinical reassessment helps clarify whether symptoms emerging during reduction reflect withdrawal phenomena, recurrence of the underlying condition, or both.
A Defining Method of the Practice
Hyperbolic Tapering
Hyperbolic tapering refers to progressively smaller dose reductions over time, reflecting how receptor occupancy changes across the dose range. In some circumstances, progressively smaller reductions are discussed as doses become lower — a dedicated guide explains the concept in depth.
Conceptual illustration only: in hyperbolic tapering, each reduction is proportionally smaller than the last. No specific schedule is universally appropriate — reductions are individualized and adjusted based on clinical response.
Dose Precision
Compounding and Dosage-Form Options
At lower doses, standard tablet strengths may limit the ability to make precise reductions, which is where compounding pharmacies may be considered in clinical tapering strategies. Compounding may be particularly useful during the final stages of a taper, when even minor dose changes can significantly affect tolerability.
In some cases, liquid formulations or specially prepared compounded preparations may be used to allow smaller, incremental reductions. This is particularly relevant in hyperbolic tapering, where dose reductions become increasingly small over time — and always requires individualized medical supervision and pharmacy coordination.
A Practical Limitation
Not every dosage form or compounding option is appropriate or available for every patient. Whether a compounded formulation is used depends on the individual taper, the stage of reduction, and clinical judgment.
Continuity of Care
An Individualized Process, Start to Finish
A deprescribing plan should be guided by a clear understanding of why the medication was prescribed, what symptoms remain active, and how the individual responds to dose reduction over time.
Who May Seek Consultation About Deprescribing
Individuals may seek consultation when prior taper attempts have been unsuccessful, when withdrawal symptoms have raised concern, when long-term treatment raises questions, or when there is uncertainty about whether dose reduction is appropriate at all.
Individuals whose prior taper attempts were unsuccessful
Those whose withdrawal symptoms have raised concern
Patients uncertain whether reduction is appropriate at all
Individuals seeking a gradual, structured tapering approach
High-functioning individuals who wish to maintain stability during reduction
Clinical Priorities
Treatment Planning Considerations
Treatment planning may involve clarifying whether dose reduction is appropriate, reviewing prior taper attempts, considering pacing and tolerability, and reassessing stability over time. In some situations, formulation or dose-precision considerations affect planning — and in some circumstances, progressively smaller reductions are discussed as doses become lower, reflecting hyperbolic dose–occupancy relationships.
The objective is not simply dose reduction, but the preservation of functional capacity and clinical stability throughout the taper. At lower doses, tapering often requires more precise adjustments, and in some cases liquid formulations or compounded preparations may be used to allow smaller, incremental reductions.
Prescribing Boundaries
In this clinical context, benzodiazepines are prescribed, when appropriate, solely as part of a structured tapering process and not for indefinite or long-term maintenance treatment. Prescribing practices are aligned with applicable state and federal regulations and are limited to clinically indicated tapering strategies.
Pharmacologic Context
Medications Commonly Associated With Deprescribing Questions
Benzodiazepines
Xanax (alprazolam), Klonopin (clonazepam), Ativan (lorazepam), and diazepam (Valium) each have dedicated tapering guides, alongside the benzodiazepine overview.
Sedative-hypnotics and gabapentinoids
Ambien (zolpidem) and gabapentin each have dedicated guides addressing rebound insomnia, withdrawal symptoms, and formulation precision.
Regulated, clinically bounded prescribing
Prescribing decisions in this context follow applicable state and federal regulations and are limited to clinically appropriate indications, including structured tapering and individualized dose reduction rather than indefinite continuation without review.
Evidence Base
Clinical Guidance and Evidence
Contemporary approaches to deprescribing emphasize gradual dose reduction, ongoing reassessment, and individualized pacing. Clinical guidance consistently recommends avoiding abrupt discontinuation and adjusting reduction schedules based on withdrawal symptoms and overall stability — reflected across the Maudsley Deprescribing Guidelines, the ASAM guideline, and the Ashton Manual.
Selected Clinical Guidelines and References
Maudsley Deprescribing Guidelines
Antidepressants, benzodiazepines, gabapentinoids, and z-drugs
American Society of Addiction Medicine (ASAM)
Joint Clinical Practice Guideline on Benzodiazepine Tapering
Ashton Manual
Benzodiazepines: how they work and how to withdraw
Authored by Christian S. Monsalve, M.D. — Board-Certified Psychiatrist, Diplomate, American Board of Psychiatry and Neurology. Last reviewed: July 2026.
This guide reflects a physician-developed approach to benzodiazepine tapering informed by contemporary clinical practice guidelines, including those from the American Society of Addiction Medicine (ASAM), the Maudsley Deprescribing Guidelines and the Ashton Manual, together with current peer-reviewed evidence regarding benzodiazepine dependence, withdrawal, deprescribing, and individualized treatment.
This content is provided for educational purposes only and should not replace individualized medical evaluation or treatment. Decisions regarding medication treatment or tapering should always be made in consultation with a qualified physician who can consider each patient’s medical history, goals, and clinical circumstances.
Clinical Perspective
The objective of tapering is not simply discontinuation, but the reduction of medication burden in a manner that preserves psychiatric stability, functional capacity, and continuity of care.
In practice, the pace of tapering is determined by the patient’s response rather than a predefined schedule, with adjustments made to maintain stability and minimize disruption. The goal is a controlled and sustainable reduction process that supports long-term outcomes — approached with precision, patience, and respect for physiologic adaptation.
Christian S. Monsalve, M.D. — Board-Certified Psychiatrist
Patient and Physician Questions
Common Questions
How are withdrawal symptoms distinguished from recurrence of illness?
Symptoms emerging during dose reduction may reflect withdrawal phenomena, recurrence of the underlying condition, or both. Careful clinical reassessment — often before any further reduction — helps clarify treatment planning.
What is hyperbolic tapering?
Hyperbolic tapering means progressively smaller dose reductions over time, reflecting how receptor occupancy changes across the dose range. A dedicated guide explains the concept in depth.
What if prior taper attempts were unsuccessful?
A prior failed taper often means the prior method was too fast, too rigid, or insufficiently individualized. Alternative pacing, greater dose precision, or reassessment of symptoms may change the outcome — it does not disqualify a patient from trying again.
Is dose reduction appropriate in every case?
No. Dose reduction is not appropriate in every case — for some patients, continuing treatment is the safer choice. A careful evaluation clarifies whether reduction aligns with clinical benefit, risk, and the patient’s goals.
Do I need a compounding pharmacy for deprescribing?
Not always. However, where dose precision becomes relevant at later stages, liquid formulations or compounded preparations may be considered when clinically appropriate.
Is telepsychiatric care available in my state?
Care is available only in jurisdictions where Christian S. Monsalve, M.D., is appropriately licensed. The current list is maintained on the States Served page.
Clinical Summary
Controlled-substance deprescribing involves individualized assessment, dose precision, attention to prior failed tapers, withdrawal sensitivity, and structured physician-guided planning.
Fixed schedules are often insufficient, and dose reductions are best guided by symptom tolerance over time. If a structured, physician-guided taper may be appropriate for you or your patient, a clinical conversation is the right place to begin. Care is available only where Dr. Monsalve is appropriately licensed.